The most commonly used system to simple classify the clinical risk of prostate cancer patients is the simplified tghree-tiers (slow-, intermediate-, and high-risk) NCCN (National Comprehensive Cancer Network, Fort Washington, PA, USA) risk groups, based ongrouping of pretreatment PSA, Gleason Score, and clinical stage. This evidence concerns the gene PSAT1 and Familial prostate cancer.